14 research outputs found
Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world
Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-US institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic.
Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality.
Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States.
Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis.
Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection
Antibody response against <i>Pseudomonas aeruginosa</i> and its relationship with immune mediators in the upper and lower airways of cystic fibrosis patients
[hiv Vaginal Viral Load In Brazilian Hiv-infected Women].
To evaluate factors associated to presence of free RNA-HIV in the vagina. Cross-sectional study with HIV-infected women, excluding those who had undergone hysterectomy, had used vaginal medication within the last 48 hours, had had unprotected sex less than 72 hours before, were pregnant, or had genital bleeding. After signing an informed consent, blood samples were obtained for T CD4 lymphocytes count and plasmatic viral load, in addition to cervico-vaginal lavage using 10 mL of sterile normal saline, later centrifuged, aliquoted and stored at - 70 degrees C to quantify free HIV-RNA. Plasmatic and vaginal viral load were measured using the kit HIV Monitor v1.5 Cobas Amplicor, Roche. Hybrid Capture test Digene was utilized for HPV (high and low risk), chlamydia trachomatis and N. gonorrhoea detection from an endocervical sample. Vaginal swab for bacterioscopy by the Gram method, evaluated according to Nugent criteria was obtained. Among 200 women evaluated, 73.5% were using HAART. The RNA-HIV was detectable in the vaginal lavage of 18 (9%), but in only one of those who had undetectable plasma viral load (0.5%). The vaginal prevalence of HIV was 24 times higher among those with detectable plasmatic HIV. Plasma viral load > 1500 copies/mL, no HAART use, reduced CD4 and bacterial vaginosis had increased prevalence of vaginal HIV-RNA, but in the adjusted statistical analysis, only the former remained significant Prevalence of vaginal HIV-RNA was low (9%). Plasmatic viral load > 1500 copies/mL, was the only risk factor for free vaginal HIV-RNA.5467-7
HIV vaginal viral load in Brazilian HIV-infected women
OBJECTIVE: To evaluate factors associated to presence of free RNA-HIV in the vagina. METHODS: Cross-sectional study with HIV-infected women, excluding those who had undergone histerectomy, had used vaginal medication within the last 48 hours, had had unprotected sex less than 72 hours before, were pregnant, or had genital bleeding. After signing an informed consent, blood samples were obtained for T CD4 lymphocytes count and plasmatic viral load, in addition to cervico-vaginal lavage using 10mL of sterile normal saline, later centrifuged, aliquoted and stored at - 70°C to quantify free HIV-RNA. Plasmatic and vaginal viral load were measured using the kit HIV Monitor v1.5 Cobas Amplicor, Roche. Hybrid Capture test Digene was utilized for HPV (high and low risk), clamydia trachomatis and N. gonorrhoae detection from an endocervical sample. Vaginal swab for bacterioscopy by the Gram method, evaluated according to Nugent criteria was obtained. RESULTS: Among 200 women evaluated, 73.5% were using HAART. The RNA-HIV was detectable in the vaginal lavage of 18 (9%), but in only one of those who had undetectable plasma viral load (0.5%). The vaginal prevalence of HIV was 24 times higher among those with detectable plasmatic HIV. Plasma viral load > 1500 copies/mL, no HAART use, reduced CD4 and bacterial vaginosis had increased prevalence of vaginal HIV-RNA, but in the adjusted statistical analysis, only the former remained significant CONCLUSION: Prevalence of vaginal HIV-RNA was low (9%). Plasmatic viral load > 1500 copies/mL, was the only risk factor for free vaginal HIV-RNA.Avaliar os fatores associados à presença de RNA-HIV na vagina. MÉTODOS: Estudo de corte transversal, em mulheres infectadas por HIV, excluindo-se aquelas com antecedente de histerectomia, as em uso de medicações vaginais nas últimas 48 horas, as que se referiram à relação sexual desprotegida há menos de 72 horas, as gestantes e aquelas com sangramento genital. Após consentimento, coletou-se amostra sanguínea para contagem de linfócitos T CD4 e carga viral plasmática de HIV, além de lavado vaginal com 10mL de solução salina, que foi centrifugado, aliquotado e armazenado em freezer -70°C para posterior quantificação de RNA-HIV livre. A mensuração de carga viral de RNA-HIV livre plasmática e vaginal foi realizada utilizando-se o kit HIV Monitor v1.5 Cobas Amplicor®, Roche. Pesquisou-se a presença de HPV de alto e baixo risco, clamídia e gonococo por Captura Híbrida II®, Digene, em amostra endocervical. Colheu-se amostra vaginal para bacterioscopia com coloração de Gram, utilizando-se os critérios de Nugent. RESULTADOS: Entre as 200 mulheres estudadas, 73,5% usavam terapia anti-retroviral (TARV) com drogas múltiplas. O RNA-HIV foi detectável no lavado vaginal de 18 delas (9%), mas em apenas uma daquelas que tinham carga viral plasmática indetectável (0,5%). A prevalência de HIV vaginal foi 24 vezes maior naquelas em que HIV plasmático era detectável. Carga viral plasmática de HIV, não usar TARV, CD4 reduzido e vaginose bacteriana aumentaram a prevalência de RNA-HIV vaginal, mas apenas a carga viral plasmática se manteve significativa na análise ajustada. CONCLUSÃO: A prevalência de RNA-HIV vaginal foi baixa (9%). A carga viral acima de 1.500 cópias/mL foi a única variável que permaneceu como fator de risco para RNA-HIV vaginal livre.OBJECTIVE: To evaluate factors associated to presence of free RNA-HIV in the vagina. METHODS: Cross-sectional study with HIV-infected women, excluding those who had undergone histerectomy, had used vaginal medication within the last 48 hours, had had unprotected sex less than 72 hours before, were pregnant, or had genital bleeding. After signing an informed consent, blood samples were obtained for T CD4 lymphocytes count and plasmatic viral load, in addition to cervico-vaginal lavage using 10mL of sterile normal saline, later centrifuged, aliquoted and stored at - 70°C to quantify free HIV-RNA. Plasmatic and vaginal viral load were measured using the kit HIV Monitor v1.5 Cobas Amplicor, Roche. Hybrid Capture test Digene was utilized for HPV (high and low risk), clamydia trachomatis and N. gonorrhoae detection from an endocervical sample. Vaginal swab for bacterioscopy by the Gram method, evaluated according to Nugent criteria was obtained. RESULTS: Among 200 women evaluated, 73.5% were using HAART. The RNA-HIV was detectable in the vaginal lavage of 18 (9%), but in only one of those who had undetectable plasma viral load (0.5%). The vaginal prevalence of HIV was 24 times higher among those with detectable plasmatic HIV. Plasma viral load > 1500 copies/mL, no HAART use, reduced CD4 and bacterial vaginosis had increased prevalence of vaginal HIV-RNA, but in the adjusted statistical analysis, only the former remained significant CONCLUSION: Prevalence of vaginal HIV-RNA was low (9%). Plasmatic viral load > 1500 copies/mL, was the only risk factor for free vaginal HIV-RNA5416771To evaluate factors associated to presence of free RNA-HIV in the vagina. METHODS: Cross-sectional study with HIV-infected women, excluding those who had undergone histerectomy, had used vaginal medication within the last 48 hours, had had unprotected sex less than 72 hours before, were pregnant, or had genital bleeding. After signing an informed consent, blood samples were obtained for T CD4 lymphocytes count and plasmatic viral load, in addition to cervico-vaginal lavage using 10mL of sterile normal saline, later centrifuged, aliquoted and stored at - 70°C to quantify free HIV-RNA. Plasmatic and vaginal viral load were measured using the kit HIV Monitor v1.5 Cobas Amplicor, Roche. Hybrid Capture test Digene was utilized for HPV (high and low risk), clamydia trachomatis and N. gonorrhoae detection from an endocervical sample. Vaginal swab for bacterioscopy by the Gram method, evaluated according to Nugent criteria was obtained. RESULTS: Among 200 women evaluated, 73.5% were using HAART. The RNA-HIV was detectable in the vaginal lavage of 18 (9%), but in only one of those who had undetectable plasma viral load (0.5%). The vaginal prevalence of HIV was 24 times higher among those with detectable plasmatic HIV. Plasma viral load > 1500 copies/mL, no HAART use, reduced CD4 and bacterial vaginosis had increased prevalence of vaginal HIV-RNA, but in the adjusted statistical analysis, only the former remained significant CONCLUSION: Prevalence of vaginal HIV-RNA was low (9%). Plasmatic viral load > 1500 copies/mL, was the only risk factor for free vaginal HIV-RN
Assessment of IgG antibodies to Pseudomonas aeruginosa in patients with cystic fibrosis by an enzyme-linked immunosorbent assay (ELISA)
Evolution of nutritional status of infants infected with the human immunodeficiency virus
Gas6 drives Zika virus-induced neurological complications in humans and congenital syndrome in immunocompetent mice
Zika virus (ZIKV) has the ability to cross placental and brain barriers, causing congenital malformations in neonates and neurological disorders in adults. However, the pathogenic mechanisms of ZIKV-induced neurological complications in adults and congenital malformations are still not fully understood. Gas6 is a soluble TAM receptor ligand able to promote flavivirus internalization and downregulation of immune responses. Here we demonstrate that there is a correlation between ZIKV neurological complications with higher Gas6 levels and the downregulation of genes associated with anti-viral response, as type I IFN due to Socs1 upregulation. Also, Gas6 gamma-carboxylation is essential for ZIKV invasion and replication in monocytes, the main source of this protein, which was inhibited by warfarin. Conversely, Gas6 facilitates ZIKV replication in adult immunocompetent mice and enabled susceptibility to transplacental infection. Our data indicate that ZIKV promotes the upregulation of its ligand Gas6, which contributes to viral infectivity and drives the development of severe adverse outcomes during ZIKV infection
International Impact of COVID-19 on the Diagnosis of Heart Disease
Background: The coronavirus disease 2019 (COVID-19) pandemic has adversely affected diagnosis and treatment of noncommunicable diseases. Its effects on delivery of diagnostic care for cardiovascular disease, which remains the leading cause of death worldwide, have not been quantified. Objectives: The study sought to assess COVID-19's impact on global cardiovascular diagnostic procedural volumes and safety practices. Methods: The International Atomic Energy Agency conducted a worldwide survey assessing alterations in cardiovascular procedure volumes and safety practices resulting from COVID-19. Noninvasive and invasive cardiac testing volumes were obtained from participating sites for March and April 2020 and compared with those from March 2019. Availability of personal protective equipment and pandemic-related testing practice changes were ascertained. Results: Surveys were submitted from 909 inpatient and outpatient centers performing cardiac diagnostic procedures, in 108 countries. Procedure volumes decreased 42% from March 2019 to March 2020, and 64% from March 2019 to April 2020. Transthoracic echocardiography decreased by 59%, transesophageal echocardiography 76%, and stress tests 78%, which varied between stress modalities. Coronary angiography (invasive or computed tomography) decreased 55% (p < 0.001 for each procedure). In multivariable regression, significantly greater reduction in procedures occurred for centers in countries with lower gross domestic product. Location in a low-income and lower–middle-income country was associated with an additional 22% reduction in cardiac procedures and less availability of personal protective equipment and telehealth. Conclusions: COVID-19 was associated with a significant and abrupt reduction in cardiovascular diagnostic testing across the globe, especially affecting the world's economically challenged. Further study of cardiovascular outcomes and COVID-19–related changes in care delivery is warranted